Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
76 hedge funds and large institutions have $60.8M invested in Mersana Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.13% less ownership
Funds ownership: 3.35% → 3.22% (-0.13%)
1% less funds holding
Funds holding: 77 → 76 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
62% less capital invested
Capital invested by funds: $162M → $60.8M (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.49M |
| 2 |
Renaissance Technologies
New York
|
+$1.46M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$659K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$553K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$536K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.96M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.64M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$1.17M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$529K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$494K |
MRSN Hedge Fund Activity: Q3 2019 in Review
76 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2019, worth a combined $60.8M — down 62% from $162M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MRSN and 6 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 33 added.
The largest buyer was BVF Inc, adding an estimated $4.49M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $5.96M.
- 76 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2019, down from 77 in Q2 2019.
- Funds reported $60.8M of Mersana Therapeutics stock for Q3 2019, down 62% quarter-over-quarter.
- 6 funds opened new Mersana Therapeutics positions in Q3 2019 and 7 closed out, a net change of -1 holder.
- The largest Mersana Therapeutics buyer in Q3 2019 was BVF Inc, an estimated $4.49M added.
- The largest Mersana Therapeutics seller in Q3 2019 was ArrowMark Colorado Holdings, an estimated $5.96M sold.
Based on aggregated 13F filings for Q3 2019.